Cell kinetics and differentiation after hormonal-induced prostatic hyperplasia in the dog.
BACKGROUND
Our aim was to characterize the immunophenotypical changes in canine prostate epithelium after hormonal-induced benign prostatic hyperplasia (BPH).


METHODS
Castrated dogs (aged 1-2 and 9-12 years) were treated with vehicle (group C), androstanediol (group A), or androstanediol plus estradiol (group AE). Surgical prostate biopsies were obtained before and after castration and after hormonal treatment. Tissue sections were stained using antibodies specific for basal cells (34betaE12), transiently proliferating (TP)/amplifying cells (RCK103), and luminal exocrine cells (RGE53).


RESULTS
Castration resulted in a marked reduction in specific immunoreactivity associated with luminal secretory cells and basal cells in young dogs. In older dogs the number of basal cells remained constant. Hormonal treatment (AE) resulted in an increased number of cells with an immunophenotype that was associated with the TP/amplifying cell compartment and hyperplastic luminal epithelium.


CONCLUSIONS
The relative increase in TP/amplifying cells in hormonally induced BPH in the dog is in line with a stem-cell-derived proliferation. Moreover, the finding of androgen-independent basal cells in the prostate of older dogs may contribute to the enhanced risk of development of BPH with increasing age.
Mahapokai
W
W
Department of Clinical Sciences of Companion Animals, Utrecht University, Utrecht, The Netherlands.
Xue
Y
Y
van Garderen
E
E
van Sluijs
F J
FJ
Mol
J A
JA
Schalken
J A
JA
D000367:Age Factors; D045930:Anabolic Agents / Q000378:metabolism / Q000633:toxicity; D015113:Androstane-3,17-diol / Q000378:metabolism / Q000633:toxicity; D000818:Animals; D000911:Antibodies, Monoclonal; D001706:Biopsy; D002455:Cell Division; D004285:Dogs; D004847:Epithelial Cells; D004958:Estradiol / Q000378:metabolism / Q000633:toxicity; D007150:Immunohistochemistry; D016130:Immunophenotyping; D007633:Keratins / Q000032:analysis / Q000502:physiology; D007700:Kinetics; D008297:Male; D009919:Orchiectomy; D011467:Prostate / Q000473:pathology*; D011470:Prostatic Hyperplasia / Q000209:etiology / Q000473:pathology*
D045930:Anabolic Agents; D000911:Antibodies, Monoclonal; D015113:Androstane-3,17-diol; D004958:Estradiol; D007633:Keratins